

Interim Phase 2 Data from COVID-19 Development Program in Collaboration with GSK

January 5, 2024

Phase 2 Study Details



- **CV0701**
 - Bivalent candidate
 - Encoding the spike protein of BA.4-5 and the original SARS-CoV-2 virus
- **CV0601**
 - Monovalent candidate
 - Encoding the spike protein of BA.4-5
- Licensed bivalent mRNA **comparator vaccine**
- Study **fully enrolled**
- Study conducted in **Australia**


Phase 2 Study Design

427 healthy adult participants aged 18 and older equally randomized between groups

CV0701	high dose	✓
CV0701	medium dose	✓
CV0701	low dose	✓
Licensed bivalent mRNA comparator		✓
CV0601	medium dose	✓


CV0601: Monovalent Candidate Encoding Omicron BA.4-5

CV0601: Reactogenicity profile



CV0601: Adjusted¹⁾ geometric mean ratios of neutralizing antibodies titers

Day 29 post- to pre-boost titers




CV0601 exhibits favorable tolerability profile and induces robust antibody boosts

1) GMR and confidence intervals are adjusted for baseline titer, age at baseline (<65 or ≥65) and prior SARS-CoV-2 infection
 2) Licensed bivalent, mRNA-based comparator vaccine

CV0601: Monovalent Candidate Encoding Omicron BA.4-5

CV0601: Adjusted¹⁾ geometric mean titers of neutralizing antibodies

Day 29 post vaccination




CV0601 elicits robust antibody responses against BA.4-5 as well as the original virus

1) GMT and confidence intervals are adjusted for baseline titer, age at baseline (<65 or ≥65) and prior SARS-CoV-2 infection
2) All GMT measured via pseudo-typed neutralization assay


3) Licensed bivalent, mRNA-based comparator vaccine

CV0701: Reactogenicity profile



CV0701: Adjusted¹⁾ geometric mean ratios of neutralizing antibodies titers

Day 29 post- to pre-booster titers



CV0701 is generally well tolerated and shows meaningful immune responses at lower doses


1) GMR and confidence intervals are adjusted for baseline titer, age at baseline (<65 or ≥65) and prior SARS-CoV-2 infection
 2) Licensed bivalent, mRNA-based comparator vaccine

CV0701: Bivalent Candidate Encoding Omicron BA.4-5 & Original SARS-CoV-2



CV0701: Adjusted¹⁾ geometric mean titers of neutralizing antibodies

Day 29 post vaccination



CV0701 antibody titers match or numerically exceed comparator titers starting at medium dose level

- 1) GMT and confidence intervals are adjusted for baseline titer, age at baseline (<65 or ≥65) and prior SARS-CoV-2 infection
- 2) All GMT measured via pseudo-typed neutralization assay
- 3) Licensed bivalent, mRNA-based comparator vaccine